Nuvalent Valuation Multiples

Nuvalent Overview

About Nuvalent

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Founded

2017

HQ

Employees

228

Website

nuvalent.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $4M

EBITDA: ($409M)

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

Nuvalent Financials

Nuvalent reported last 12-month revenue of $4M and negative EBITDA of ($409M).

In the same LTM period, Nuvalent generated $4M in gross profit, ($409M) in EBITDA losses, and had net loss of ($428M).

Nuvalent P&L

In the most recent fiscal year, Nuvalent reported revenue of — and EBITDA of ($397M).

Nuvalent expects next 12-month revenue of XXX and NTM EBITDA of XXX

Nuvalent Stock Performance

Nuvalent has current market cap of $8B, and enterprise value of $7B.

Nuvalent's stock price is $107.71.

Nuvalent Valuation Multiples

Nuvalent trades at 1720.5x EV/Revenue multiple, and (17.3x) EV/EBITDA.

Nuvalent Financial Valuation Multiples

As of April 19, 2026, Nuvalent has market cap of $8B and EV of $7B.

Equity research analysts estimate Nuvalent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Nuvalent has a P/E ratio of (19.8x).

Nuvalent Margins & Growth Rates

Nuvalent's revenue in the last 12 month grew by 1460%.

Nuvalent's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.

Nuvalent Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Nuvalent M&A Activity

Nuvalent acquired XXX companies to date.

Last acquisition by Nuvalent was on XXXXXXXX, XXXXX. Nuvalent acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Nuvalent Investment Activity

Nuvalent invested in XXX companies to date.

Nuvalent made its latest investment on XXXXXXXX, XXXXX. Nuvalent invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).